CN103356681A - Application of Houttuynoid A in preparation of medicines for treating myocardial ischemia - Google Patents
Application of Houttuynoid A in preparation of medicines for treating myocardial ischemia Download PDFInfo
- Publication number
- CN103356681A CN103356681A CN2013102580420A CN201310258042A CN103356681A CN 103356681 A CN103356681 A CN 103356681A CN 2013102580420 A CN2013102580420 A CN 2013102580420A CN 201310258042 A CN201310258042 A CN 201310258042A CN 103356681 A CN103356681 A CN 103356681A
- Authority
- CN
- China
- Prior art keywords
- houttuynoid
- myocardial ischemia
- preparation
- application
- medicines
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to an application of Houttuynoid A in preparation of medicines for treating myocardial ischemia. The application of the Houttuynoid A in preparation of medicines for treating myocardial ischemia provided by the invention is disclosed for the first time. As the framework type is a brand new framework type and the inhibiting activity of the Houttuynoid A to myocardial ischemia is unimaginably strong, the probability of giving any enlightenment by other compounds does not exist. The Houttuynoid A has remarkable substantial characteristics and meanwhile has remarkable progress in treatment of myocardial ischemia.
Description
Technical field
The present invention relates to the application of Houttuynoid A in preparation treatment or prevention myocardial ischemia drug.
Background technology
The inventor finds by a large amount of experiment, and Houttuynoid A has and resists myocardial ischemia/pharmacological action of reperfusion injury the medical usage with prevention or treatment myocardial ischemia disease.
The compound H outtuynoid A that the present invention relates to is one and delivered (Chen in 2012, S. D. et al., 2012. Houttuynoid A-E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 17724 – 1775.) New skeleton compound, this chemical compound has brand-new framework types, present purposes only relates to anti-herpes simplex virus activity (Chen, S. D. et al., 2012. Houttuynoid A-E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 17724 – 1775.), belong to open first for the purposes of the Houttuynoid A that the present invention relates in the preparation medicaments for resisting myocardial ischemia, because framework types belongs to brand-new framework types, and its inhibition for myocardial ischemia is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, be used for resisting myocardial ischemia simultaneously obviously have significant progress.
Summary of the invention
The invention provides the application in the medicine of Houttuynoid A preparation treatment or prevention Ischemic/reperfusion.
The inventor has the effect for the treatment of or prevention myocardial ischemia drug disease by the Houttuynoid A that experimental results show that in the specific embodiment.
Described compound H outtuynoid A structure is shown in formula I:
Formula I
The purposes of the Houttuynoid A that the present invention relates in the preparation medicaments for resisting myocardial ischemia belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for myocardial ischemia is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, be used for resisting myocardial ischemia simultaneously obviously have significant progress.
The specific embodiment
The preparation method of compound H outtuynoid A involved in the present invention is referring to document (Chen, S. D. et al., 2012. Houttuynoid A-E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 17724 – 1775.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
Embodiment 1: the preparation of compound H outtuynoid A tablet involved in the present invention:
Get 20 and digest compound Houttuynoid A, add conventional adjuvant 180 grams of preparation tablet, mixing, conventional tablet machine are made 1000.
Embodiment 2: the preparation of compound H outtuynoid A capsule involved in the present invention:
Get 20 and digest compound Houttuynoid A, add conventional adjuvant such as starch 180 grams of preparation capsule, mixing is encapsulatedly made 1000.
Further specify its pharmaceutically active below by pharmacodynamic experiment.
Experimental example: Houttuynoid A is on the impact of myocardial ischemia/reperfusion injury in rats
(1) experiment material: SD rat, male and female dual-purpose, body weight 190 ~ 210g.
(2) method and result
1) experimental technique
The acute myocardial ischemia experiment that pituitrin is induced: rat is divided into 5 groups at random: positive drug matched group, model control group, 3 groups of administration groups, 8 every group.Administration group gastric infusion, positive drug matched group and model control group give the distilled water gavage with volume every day, and each organizes continuous gavage 7d.All 1.5 ~ 2.0h lumbar injection pentobarbital sodium, 30 mg/kg anesthesia after the 7th day gavage adopts MS2302 multimedia biological signal collecting analytical system to continue record standard II lead electrocardiogram.Finish in positive drug matched group, model control group and administration group sublingual vein injection of pituitrin 5 IU/kg(5s, the positive drug matched group is 10 min lumbar injection nitroglycerin, 5 mg/kg before injection of pituitrin) the Electrocardiographic variation of continuous record 15 min behind 10 min.If occur one of following variation in the electrocardiogram: the T ripple is low flat, two-way, is inverted, and ST section level moves down 〉=0.05 mV, remembers 1 minute.At last the total points of every rat is analyzed, as reducing after the medication score, the prompting myocardial ischemia is improved.Represent that with changes in heart rate percentage rate before and after the injection of pituitrin medicine is on the impact of heart rate.
Cardiac muscle ischemia resisting reperfusion injury experiment: rat is divided into 5 groups at random: positive drug matched group, model control group, 3 groups of administration groups, 8 every group.Administration group gastric infusion, positive drug matched group and model control group give the distilled water gavage with volume every day, and each organizes continuous gavage 7d.Record standard II lead electrocardiogram after the rats by intraperitoneal injection pentobarbital sodium 30 mg/kg anesthesia.Tracheal intubation meets artificial respirator (1.0 mlg
-1Min
-1), open the thoracic cavity at the 4th ~ 5 intercostal, expose heart, at the pulmonary conus left border, left auricle lower edge 1mm place is with 320 silk thread ligation ramus descendens anterior arteriae coronariae sinistraes (positive drug matched group 3 min sublingual veines before following coronary artery occlusion are injected Propranolol 1.0 mg/kg).Behind ligation 30 min, cut off ligature, fill with again 30 min.Take out fast heart, rinse well with 0.9% sodium chloride.Myocardium sheet is placed in 1% the TTC solution, in 37 ℃ of hatching 5 min.Dyestuff unnecessary on the myocardium sheet is removed in immediately water flushing after the dyeing.Cut off the non-infarcted region cardiac muscle that each myocardium sheet is colored, undyed infarcted myocardium and ischemic myocardium are weighed.
Hemodynamics experiment: rat is divided into 5 groups at random: positive drug matched group, model control group, 3 groups of administration groups, 8 every group.Administration group gastric infusion, positive drug matched group and model control group give the distilled water gavage with volume every day, and each organizes continuous gavage 5d.Lumbar injection urethane 10 mg/kg anesthesia in the 6th day.Record standard II lead electrocardiogram.Vertically cut right skin of neck, separate right common carotid artery, insert the left ventricular catheter that has been full of heparin 0.9% sodium chloride, conduit is slowly inserted left ventricular cavity.Cut the left lower extremity inside skin, separate femoral artery, insert ductus arteriosus.The cut-in pressure transducer is transported to multimedia bio signal monitor to signal and is observed.Behind balance 30 min, each hemodynamic index before the record administration.
So data all represent with x ± s, experimental group and matched group data analysis are with the sided t check of two sample means.
2) result
The ischemia/reperfusion injury experimental result shows, myocardial Mass Measured percentage ratio sees Table respectively 1 under administration group, positive drug matched group, model control group myocardial infarction and the ligature.
Table 1 Houttuynoid A is on the impact of scheming weight ratio under myocardial infarction and the ligature
Compare * * p＜0.01, * p＜0.05 with model
Houttuynoid A sees Table 2 to the impact of the acute myocardial ischemia that pituitrin causes.
The impact of the acute myocardial ischemia that table 2 Houttuynoid A causes pituitrin
Compare * * p＜0.01, * p＜0.05 with model
Conclusion: Houttuynoid A can reduce the generation of myocardial infarction, and Houttuynoid A can obviously change the variation of electrocardio degree, does not change heart rate.Above experiment can illustrate, Houttuynoid A can prevent and treat myocardial ischemia.
Claims (1)
1.Houttuynoid A application in the myocardial ischemia drug in treatment or prevention, described compound H outtuynoid A structure as
Formula IShown in:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310258042.0A CN103356681B (en) | 2013-06-24 | 2013-06-24 | The application of Houttuynoid A in preparation treatment myocardial ischemia drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310258042.0A CN103356681B (en) | 2013-06-24 | 2013-06-24 | The application of Houttuynoid A in preparation treatment myocardial ischemia drug |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103356681A true CN103356681A (en) | 2013-10-23 |
| CN103356681B CN103356681B (en) | 2015-11-25 |
Family
ID=49359497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310258042.0A Expired - Fee Related CN103356681B (en) | 2013-06-24 | 2013-06-24 | The application of Houttuynoid A in preparation treatment myocardial ischemia drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103356681B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102670583A (en) * | 2012-06-11 | 2012-09-19 | 新疆德泓生物科技有限公司 | Application of flavonoids in moldavica dragonhead in the preparation of myocardial ischemic antagonist |
-
2013
- 2013-06-24 CN CN201310258042.0A patent/CN103356681B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102670583A (en) * | 2012-06-11 | 2012-09-19 | 新疆德泓生物科技有限公司 | Application of flavonoids in moldavica dragonhead in the preparation of myocardial ischemic antagonist |
Non-Patent Citations (1)
| Title |
|---|
| CHEN, S. D. ET AL.: "Houttuynoid A-E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata", 《ORGANIC LETTERS 》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103356681B (en) | 2015-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102423308A (en) | Two bromophenol compounds and application of pharmaceutically-acceptable salts of two bromophenol compounds in preparation of protection drug | |
| CN103638012B (en) | Application of Myrtucommuacetalone in medicine for treatment of myocardial ischemia | |
| CN102988351A (en) | Application of Aphanamixoid A for preparing medicine for treating myocardial ischemia | |
| CN103520170B (en) | Kadcoccitones A application in preparation treatment myocardial ischemia drug | |
| CN103356681A (en) | Application of Houttuynoid A in preparation of medicines for treating myocardial ischemia | |
| CN103381182A (en) | Application of Houttuynoid C in drug for treatment of myocardial ischemia | |
| CN103768051B (en) | The application of Eryngiolide A in preparation treatment myocardial ischemia drug | |
| CN103381178A (en) | Application of Houttuynoid D in drug for treatment of myocardial ischemia | |
| CN103356676A (en) | Application of Houttuynoid E in medicine for treating myocardial ischemia | |
| CN103356595A (en) | Application of Chukrasone B in preparation medicines for treating myocardial ischemia | |
| CN103393703A (en) | Application of Houttuynoid B in drugs treating myocardial ischemia | |
| CN103356647A (en) | Application of Chukrasone A in preparation medicines for treating myocardial ischemia | |
| CN105412073A (en) | Application of Spirooliganone B in preparation of myocardial ischemia treatment drug | |
| CN103356546A (en) | Application of Sarcaboside B in medicine used for treating myocardial ischemia | |
| CN103479609A (en) | Application of Scopariusins in preparation of myocardial ischemia treatment medicines | |
| CN103751182B (en) | The application of a kind of compound in treatment myocardial ischemia drug | |
| CN103393657A (en) | Application of Sarcaboside A to medicament for treatment of myocardial ischemia | |
| CN106344579A (en) | Application of Fistulains A in drugs for myocardial ischemia treatment | |
| CN102861035B (en) | Application of Gypensapogenin B in medicine for treating myocardial ischemia | |
| CN105412068A (en) | Application of Rearranged abietane diterpenoid in preparation of drugs for treating myocardial ischemia | |
| CN105250269A (en) | Application of Nagelamides X in preparation of drug for treating myocardial ischemia | |
| CN102895239A (en) | Application of Gypensapogenin A in drugs for treating myocardial ischemia | |
| CN103340886A (en) | Application of Polyflavanostilbene A in preparation of medicine for treating myocardial ischemia | |
| CN105380940A (en) | Use of Rhodomicranols B in preparation of drug for treating myocardial ischemia | |
| CN103263424A (en) | Application of Myriberine A in preparation of medicine for treating myocardial ischemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Yang Guixia Inventor after: Zheng Xin Inventor after: Du Pingping Inventor before: Ding Shengyu |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20151013 Address after: 261500, room 1, unit 1, building 301, community hospital of traditional Chinese medicine, three community hospital, East China Town, Gaomi City, Weifang, Shandong Applicant after: Yang Guixia Address before: 210009 Gulou District, Jiangsu, Nanjing Gu Ping Kong, No. 4 Applicant before: Ding Shengyu |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151125 Termination date: 20160624 |